This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Gilead Sciences, Inc.
Drug Names(s): emtricitabine, Coviracil, FTC
Description: Emtriva, (also known as emtricitabine or FTC), is an anti-HIV treatment in a class of drugs called Nucleoside Reverse Transcriptase Inhibitors (NRTIs, or Nukes). This type of drug works by blocking HIV from completing an early step of the process HIV uses to make new copies of itself in already infected cells.
Deal Structure: In April 1996, Triangle Pharmaceuticals, acquired by Gilead in January 2003, obtained an exclusive worldwide license to all of Emory Universitys rights to purified forms of emtricitabine for use in the HIV and HBV indications. Prior to July 2005, Gilead paid royalties to Emory with respect to worldwide net sales of product containing emtricitabine. In July 2005, Gilead and Royalty Pharma purchased 65% and 35%, respectively, of the royalty interest owned by Emory in exchange for the elimination of the emtricitabine royalties payable to Emory. Since July 2005, Gilead has paid royalties with respect to worldwide net sales of products containing emtricitabine directly to Royalty Pharma at a rate proportional to its share of the purchase price. Also in July 2005, Gilead made a payment to Emory in connection with the amendment and restatement of its existing license agreement with Emory, as it pertained to Gilead's obligation to develop emtricitabine for the hepatitis B indication....See full deal structure in Biomedtracker
Partners: Japan Tobacco Inc. Royalty Pharma AG
Pink Sheet Gilead Emtriva approval
Additional information available to subscribers only: